Lercanidipin Accord

Lercanidipine Hydrochloride, the active ingredient in Lercanidipin Accord, is a calcium channel blocker presented as an oral tablet for oral use. It treats hypertension in adult patients by lowering elevated blood pressure. GNH USA supplies Lercanidipin Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lercanidipine is indicated for the management of hypertension, a condition characterized by chronically elevated arterial pressure. It works within the vascular system to achieve blood‑pressure control. - Essential hypertension: reduces systolic and diastolic blood pressure in patients with primary hypertension. - Isolated systolic hypertension: lowers elevated systolic pressure in older adults. - Secondary hypertension: assists in blood‑pressure control when hypertension is due to identifiable causes.

Lercanidipine may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Headache: mild to moderate headache occurring shortly after dosing. - Flushing: transient warmth and redness of the skin. - Peripheral edema: swelling of the ankles or lower legs. - Dizziness: light‑headed sensation, especially when standing quickly. - Tachycardia: increased heart rate. - Palpitations: awareness of heart beating.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure leading to fainting. - Myocardial infarction: rare occurrence of heart attack. - Hepatic dysfunction: abnormal liver enzyme elevations. - Allergic reactions: rash, pruritus, or angioedema. - Cardiac arrhythmias: irregular heart rhythms.

Before initiating therapy, clinicians should consider several safety aspects. - Blood pressure monitoring: regularly assess to avoid excessive hypotension. - Hepatic impairment: use with caution in patients with liver disease. - Concomitant antihypertensives: adjust doses to prevent additive effects. - Sudden discontinuation: avoid abrupt stopping to reduce rebound hypertension. - Pregnancy and lactation: evaluate risk‑benefit, as safety data are limited. - Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Lercanidipine can interact with several drug classes, influencing its efficacy and safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase plasma concentrations. - Grapefruit juice: can markedly raise drug levels. - Other potent vasodilators: risk of severe hypotension.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampicin): may reduce effectiveness. - Diuretics: may enhance antihypertensive effect. - Beta‑blockers: combined use may require dose adjustments. - NSAIDs: can attenuate blood‑pressure‑lowering effect.